Neurocrine Biosciences NBIX Balance Sheet (2010-2026)

NASDAQ NBIX
$141.84 +3.49 (+2.52%)
At close: Sep 30, 2026 · 4:00 PM EDT
Reported Financials

Neurocrine Biosciences Quarterly Balance Sheet

Periods 65 quarters
Latest Jun 2026

Neurocrine Biosciences reported total assets of $5359.10M and total liabilities of $1665.50M for the quarter ended Jun 2026, up 37.8% year over year. This balance sheet covers 65 quarters of results from Jun 2010 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Balance Sheet Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Assets
Current Assets
Cash & EquivalentsCash & Equiv.
311.10M344.00M270.20M163.30M212.20M270.70M103.80M160.20M293.70M259.10M396.30M139.70M349.10M233.00M194.10M264.00M340.20M713.00M266.50M332.40M
Short-term InvestmentsInvestments (Current)
454.80M370.50M394.70M485.00M587.20M726.40M790.80M816.50M801.40M780.50M814.30M899.20M878.90M843.10M749.40M711.60M774.60M767.40M1,049.70M57.40M
Cash & Current Investments
765.90M714.50M664.90M648.30M799.40M997.10M894.60M976.70M1,095.10M1,039.60M1,210.60M1,038.90M1,228.00M1,076.10M943.50M975.60M1,114.80M1,480.40M1,316.20M389.80M
Receivables - NetNet Receivables
163.80M185.50M263.50M279.00M301.20M350.00M391.60M387.60M417.80M439.30M450.70M468.20M481.10M479.10M516.00M595.70M728.00M686.80M768.10M887.00M
Receivables
163.80M185.50M263.50M279.00M301.20M350.00M391.60M387.60M417.80M439.30M450.70M468.20M481.10M479.10M516.00M595.70M728.00M686.80M768.10M887.00M
Raw Materials
11.20M12.00M21.50M18.10M21.30M23.70M33.70M31.90M
Work In Process
3.60M5.60M9.70M12.00M12.00M10.60M10.90M13.80M
Finished Goods
15.70M17.50M12.30M7.50M10.40M11.50M12.80M13.60M
Inventory
25.50M30.50M29.00M29.30M37.00M35.10M33.40M31.70M28.80M38.30M37.20M42.50M45.80M57.40M59.10M56.90M69.30M69.00M64.50M104.20M
Prepaid Assets
48.50M178.10M170.70M224.80M217.10M
Current Assets
1,005.70M972.80M1,018.20M1,019.30M1,205.50M1,453.50M1,432.80M1,496.60M1,649.90M1,607.00M1,799.00M1,669.80M1,876.60M1,724.70M1,637.90M1,748.90M2,158.40M2,522.70M2,436.10M1,637.50M
Non-Current Assets
Property, Plant & Equipment (Net)PP&E (Net)
51.10M58.60M63.90M66.80M60.90M58.60M62.80M65.60M68.80M70.80M75.30M80.10M80.00M82.60M87.00M91.70M97.30M89.80M90.90M90.50M
Long-Term Investments
513.70M560.70M541.00M405.20M362.60M299.40M244.60M342.60M454.70M687.50M700.40M637.80M643.90M739.50M815.30M873.80M998.50M1,063.00M1,331.00M147.30M
Goodwill
5.40M5.60M5.70M5.50M5.80M5.70M5.70M6.10M5.70M6.10M6.00M500.60M
Intangibles
37.20M37.20M36.90M34.90M35.50M34.30M33.50M34.50M36.50M36.40M37.20M35.70M4.70M2,226.00M
Goodwill & Intangibles
42.60M42.80M42.60M40.40M41.30M40.00M39.20M40.60M42.20M36.40M37.20M35.70M10.80M6.00M2,726.60M
Long-Term Deferred Tax
310.40M315.10M325.30M328.40M319.40M305.90M337.40M379.00M383.20M362.60M378.20M419.50M454.40M485.70M499.40M536.80M368.50M320.30M381.40M8.90M
Other Non-Current Assets
3.20M4.40M10.10M10.00M10.50M25.00M24.90M35.90M43.10M49.60M50.90M57.80M61.60M52.00M15.30M21.60M20.30M48.70M73.60M59.30M
Non-Current Assets
1,011.60M1,099.70M1,126.30M986.40M937.90M915.20M927.00M1,116.50M1,198.30M1,644.40M1,673.40M1,635.20M1,658.40M1,994.00M2,049.80M2,140.90M2,107.30M2,108.80M2,470.10M3,721.60M
Assets
2,017.30M2,072.50M2,144.50M2,005.70M2,143.40M2,368.70M2,359.80M2,613.10M2,848.20M3,251.40M3,472.40M3,305.00M3,535.00M3,718.70M3,687.70M3,889.80M4,265.70M4,631.50M4,906.20M5,359.10M
Liabilities
Current Liabilities
Accounts Payables
205.90M225.80M235.90M265.70M297.80M347.60M355.70M391.60M503.00M448.80M417.20M358.50M392.70M461.60M475.20M489.50M584.30M674.30M773.00M808.30M
Payables
205.90M225.80M235.90M265.70M297.80M347.60M355.70M391.60M503.00M448.80M417.20M358.50M392.70M461.60M475.20M489.50M584.30M674.30M773.00M808.30M
Accumulated Expenses
Other Accumulated Expenses
20.00M20.00M17.60M20.00M18.10M20.70M18.40M21.20M18.70M35.90M36.70M40.00M37.00M46.10M47.70M56.80M53.70M69.10M58.70M66.20M
Short term Debt
169.20M169.40M169.70M169.90M170.10M122.80M
Current Deferred Revenue
Total Current Liabilities
225.90M245.80M253.50M285.70M485.10M537.70M374.10M582.50M691.60M654.80M712.90M398.50M429.70M507.70M522.90M546.30M638.00M743.40M831.70M874.50M
Non-Current Liabilities
Convertible Debt
330.70M335.10M377.70M169.00M169.50M
Non-Current Deffered Revenue
Non-Current Deferred Tax LiabilityNon-Current Deferred Tax
91.50M
Operating Leases
106.40M105.30M102.50M99.60M96.60M93.50M90.40M89.10M85.90M258.30M252.90M256.20M251.40M455.10M447.50M439.10M428.40M415.30M406.20M401.80M
Other Non-Current Liabilities
8.30M12.30M19.70M28.00M17.10M29.70M41.30M88.50M68.60M106.30M136.20M141.10M135.00M166.20M181.60M210.10M195.70M219.70M260.90M297.70M
Total Non-Current Liabilities
663.00M686.20M733.70M554.30M581.70M631.20M634.00M671.60M777.50M913.10M950.10M654.70M681.10M962.80M970.40M985.40M1,066.40M1,158.70M1,237.90M1,367.80M
Total Liabilities
671.30M698.50M753.40M582.30M598.80M660.90M675.30M760.10M846.10M1,019.40M1,086.30M795.80M816.10M1,129.00M1,152.00M1,195.50M1,262.10M1,378.40M1,498.80M1,665.50M
Shareholder's Equity
Total Debt
169.20M169.40M169.70M169.90M170.10M122.80M
Common Equity
1,346.00M1,374.00M1,391.10M1,423.40M1,544.60M1,707.80M1,684.50M1,853.00M2,002.10M2,232.00M2,386.10M2,509.20M2,718.90M2,589.70M2,535.70M2,694.30M3,003.60M3,253.10M3,407.40M3,693.60M
Liabilities and Shareholders Equity
2,017.30M2,072.50M2,144.50M2,005.70M2,143.40M2,368.70M2,359.80M2,613.10M2,848.20M3,251.40M3,472.40M3,305.00M3,535.00M3,718.70M3,687.70M3,889.80M4,265.70M4,631.50M4,906.20M5,359.10M
Retained Earnings
-628.50M-635.80M-547.40M-564.30M-495.80M-406.80M-483.40M-387.90M-304.80M-157.10M-113.70M-48.70M81.10M29.20M-5.30M84.50M294.00M447.70M589.60M724.00M

Neurocrine Biosciences Balance Sheet API

Pull Neurocrine Biosciences's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=NBIX&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEY